Bugatinib belongs to the fourth generation of targeted drugs and is also a second generation ALK inhibitor. Bugatinib belongs to the fourth-generation targeted class of drugs and is also a second-generation ALK inhibitor. Bugatinib, as a monotherapy, is primarily indicated for the first-line treatment of adult patients with mesenchymal lymphoma kinase-positive metastatic non-small cell lung cancer. Adverse reactions such as dyspnea, cough, fever, blurred vision, hypertension, hyperglycemia, chest pain, headache, dizziness, frequent urination, hunger, nausea, malaise, confusion, slow heart rate, muscle pain, and weight loss may occur during the application of this drug. It is recommended to follow the doctor’s instructions to standardize the use of medication therapy, avoid abuse of drugs, so as to avoid adverse reactions but aggravate the condition.